Precigen/PGEN

$1.62

5.88%
-
1D1W1MYTD1YMAX

About Precigen

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company, which is advancing the gene and cell therapies using precision technology to target the urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. Its lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. AG019 ActoBiotics is a disease-modifying approach to induce antigen-specific immune tolerance to prevent, delay or reverse type-1 diabetes (T1D).

Ticker

PGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Randal Kirk

Employees

209

Headquarters

Germantown, United States

Precigen Metrics

BasicAdvanced
$363.42M
Market cap
-
P/E ratio
-$0.37
EPS
1.71
Beta
-
Dividend rate

What the Analysts think about Precigen

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
486.42% upside
High $14.00
Low $6.00
$1.62
Current price
$9.50
Average price target

Precigen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,515.38% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.3M
-23.53%
Net income
$-19.7M
-2.96%
Profit margin
-1,515.38%
26.9%

Precigen Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.56%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.11
-$0.10
-$0.08
-$0.08
-
Expected
-$0.10
-$0.09
-$0.10
-$0.08
-$0.08
Surprise
10%
9.59%
-20%
2.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Precigen stock

Buy or sell Precigen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing